"Duke's Cary-based cancer center makes it easy for you to receive high-quality cancer treatment in an outpatient center close to your home. Our team cares for men and women with different types of cancers, including breast cancer, colon cancer, gastrointestinal cancers, melanoma, prostate cancer, and kidney cancer. Your appointments at this cancer center in Cary may include lab work, consultations with surgical oncologists, visits with medical oncologists, and treatments in our open infusion suite."

During the past decade, Duke Cancer Institute Cary conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 1 clinical trials were completed, i.e. on average, 12.5% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Duke Cancer Institute Cary" #1 sponsor was "Celgene" with 2 trials, followed by "Duke University" with 2 trials sponsored, "National Cancer Institute (NCI)" with 2 trials sponsored, "Andrew J. Armstrong, MD" with 1 trials sponsored and "Daniel George, MD" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Duke Cancer Institute Cary" #1 collaborator was "National Cancer Institute (NCI)" with 2 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Janssen Scientific Affairs, LLC" with 1 trials as a collaborator and "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Duke Cancer Institute Cary" are "Prostate Cancer" (4 trials), "Breast Cancer" (1 trials), "Chronic Lymphocytic Leukemia" (1 trials), "Gastric Neuroendocrine Carcinoma" (1 trials) and "Intestinal Neuroendocrine Carcinoma" (1 trials). Many other conditions were trialed in "Duke Cancer Institute Cary" in a lesser frequency.

Most popular intervention types in "Duke Cancer Institute Cary" are "Drug" (7 trials), "Other" (4 trials), "Biological" (2 trials), "Procedure" (2 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Apalutamide" (2 trials), "Biospecimen Collection" (2 trials), "Computed Tomography" (2 trials), "Quality-of-Life Assessment" (2 trials) and "Questionnaire Administration" (2 trials). Other intervention names were less common.

The vast majority of trials in "Duke Cancer Institute Cary" are 6 trials for "All" genders, 5 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Duke Cancer Institute Cary". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Duke Cancer Institute Cary, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Duke Cancer Institute Cary, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".